Buying and sourcing
Why the same molecule has four prices at once
On this page
A published list price, an insurer's net price, a manufacturer's cash price and a government programme price are not four guesses at one number. They are four different quantities.
The list price is a starting point in a rebate system. Rebates are negotiated after it is set and are not public, so the list figure can sit several times above anything anyone actually pays.
Cash prices exist because a person with no insurance is outside the rebate system entirely — there is no rebate to negotiate, so the manufacturer prices directly.
Nothing about the molecule changes between these four numbers. What changes is who is paying, through which intermediary, under which contract.
This page explains a pricing structure. It does not tell you what you will pay, which channel to use, or whether any product is appropriate for anyone. Figures appear only as illustrations of the structure and carry the date they were read.
Four numbers, four mechanisms
The instinct when confronted with a $149 price and a $1,349 price for the same product is that one of them is fake. Neither is. They are produced by different mechanisms, and each is exactly as real as the contract behind it.1
Sorting them out is mostly a matter of asking, for each number, who pays it and to whom. Once that question is asked of each figure separately, the spread stops being mysterious.
One: the list price
The list price is the manufacturer's published reference figure. It is the number TrumpRx displays in the struck-through position — $1,349 for Wegovy, $1,028 for Ozempic, $1,087 for Zepbound as those pages read on 1 August 2026 — and it functions as the starting point from which everything else is subtracted.1
It is the most visible number and the least informative one. It is set by the manufacturer, it is not the outcome of any negotiation, and outside a few uninsured cash transactions it is not what changes hands. Its main practical use is as a denominator: it is what makes a discount expressible as a percentage.
Two: the net price
The net price is what the manufacturer keeps after rebates, discounts and fees are paid back out of the list price to the intermediaries in the chain. It is the closest figure to an economic reality, and it is the one you cannot look up, because those rebate contracts are confidential.
The Federal Trade Commission's interim staff report on pharmacy benefit managers is the most substantial public account of that layer — the vertically integrated middlemen who negotiate rebates, set formularies and decide which products a plan covers and on what terms. Read alongside a list price, it explains why a large published number and a small paid number are not in contradiction.4
Three: the cash or manufacturer-direct price
A person paying cash has no plan, no formulary and therefore no rebate. The entire apparatus that separates list from net has nothing to act on. That is why manufacturer-direct pricing can be published at all: there is no confidential contract to protect, so a number can simply be put on a web page.7
It also explains the shape of those offers. Because the manufacturer is selling directly rather than buying formulary position, the price it sets is a commercial decision it can revise, condition and time-limit at will — which is precisely what the footnotes on those pages do. Novo Nordisk's self-pay pen figure applies to two monthly fills through 31 December 2026 and then steps to $349; Lilly publishes a self-pay range for the Zepbound pen running from $299 to $699 a month by presentation.23
Four: the programme price
The fourth mechanism is statutory rather than commercial. Under the Medicare Drug Price Negotiation Program, CMS publishes selected drugs and the negotiated prices that apply to them, with the applicable year attached. Those prices are the product of a process defined in law, not of a private negotiation, and they apply to a defined population rather than to anyone who turns up.5
Manufacturer bridge programmes for Medicare beneficiaries sit alongside that, again with their own published figures and their own eligibility rules. Both manufacturers describe such a programme at $50 a month for eligible Part D beneficiaries, with prior authorisation required.23
The fifth price, and why it is not on the list
There is a price attached to compounded and unapproved supply, and it is usually the lowest number anyone has seen. It is excluded from the comparison above because it prices a different category of thing.
FDA's own explainer states that compounded drugs are not FDA-approved, and that the agency does not verify their safety, effectiveness or quality before marketing. A price for a product whose identity, purity and sterility have not been reviewed is not a cheaper version of the price above it. It is a number attached to a different object, and lining the two up in a table implies an equivalence that has not been established.6
What follows from all this
- A percentage discount is only meaningful against a stated baseline. "70% off" against list is a different claim from "70% off" against a cash price.
- Two prices for the same molecule are not evidence that one seller is honest and another is not. They are usually evidence that the two are transacting through different systems.
- The number that most affects an individual is rarely the one in the headline. It is the eligibility condition in the footnote.
- Any price you record should carry its channel and its reading date, or it cannot be compared to anything later.123
If nobody pays the list price, why does it exist?
Because it is the reference point everything else is calculated from — rebates, discounts and several statutory formulas are all expressed relative to it. It also does get paid, occasionally, by people transacting outside any plan or programme, which is one reason it is not merely notional.
Is the cash price a trick to get people off insurance?
This page does not attribute motives. What it can say is structural: a cash transaction has no rebate layer, so a manufacturer selling directly is setting a price rather than negotiating formulary position. The published conditions and expiry dates on those offers are on the sellers' own pages and are worth reading before drawing conclusions.
Where can I look up the net price?
You cannot. Rebate contracts between manufacturers and pharmacy benefit managers are confidential. The FTC's interim staff report on those intermediaries is the most detailed public description of the layer, and even it does not publish per-product net prices.
Sources
- Secondary source
- Secondary sourceSave on Wegovy — coverage and savingsNovo Nordisk, 2026www.wegovy.com/coverage-and-savings/save-on-wegovy.html ↗↩ Back to text
- Secondary sourceZepbound coverage and savingsEli Lilly and Company, 2026www.zepbound.lilly.com/coverage-savings ↗↩ Back to text
- RegulatoryPharmacy Benefit Managers: The Powerful Middlemen Inflating Drug Costs and Squeezing Main Street Pharmacies (interim staff report)U.S. Federal Trade Commission, 2024www.ftc.gov/reports/pharmacy-benefit-managers-report ↗↩ Back to text
- RegulatoryMedicare Drug Price Negotiation Program: Selected Drugs and Negotiated PricesCenters for Medicare & Medicaid Services, 2026www.cms.gov/initiatives/medicare-prescription-drug-affordability ↗↩ Back to text
- RegulatoryCompounding and the FDA: Questions and AnswersU.S. Food and Drug Administration, 2026www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-que ↗↩ Back to text
- Secondary sourceNovoCare Pharmacy — self-pay pricingNovo Nordisk, 2026www.novocare.com/pharmacy.html ↗↩ Back to text